← Back to headlines
Piper Sandler Lowers Akebia Therapeutics Price Target to $4 Following Year-End Reports
Piper Sandler has reduced its price target for Akebia Therapeutics (AKBA) to $4, updating its estimates after the company's year-end reports.
20 Feb, 00:28 — 20 Feb, 00:28
ℹOnly 1 source covers this story
